Skip to main content

Table 1 The characteristics and the parameters of all patients at baseline and after treatment

From: Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?

n = 60 Baseline After treatment p*
Age (year) 58.3 ± 14.1
Sex (male/female) 14/46
Disease duration (year) 13.3 ± 12.4
Steinbrocker stage (I/II/III/IV) 7/14/21/18
Steinbrocker class (1/2/3/4) 14/27/13/6
Concomitant MTX (%) 55
MTX dosage (mg/week) 8.91 ± 2.65
Concomitant PSL (%) 45
PSL dosage (mg/day) 3.70 ± 1.86
Smoking history (%) 10
ACPA positive (%) 80
CRP (mg/dl) 2.07 ± 2.21 0.50 ± 1.05 < 0.01
ESR (mm/h) 62.6 ± 31.4 35.3 ± 27.0 < 0.01
WBC (/μl) 6610 ± 2140 5582 ± 2067 < 0.01
RF (mg/dl) 256.0 ± 876.9 162.7 ± 551.9 0.43
ACPA (U/ml) 91.5 ± 117.1 75.2 ± 96.1 0.36
MMP-3 (ng/ml) 261.30 ± 243.82 118.65 ± 129.42 < 0.01
DAS28-CRP 4.07 ± 1.23 2.35 ± 1.01 < 0.01
Joints SUV 2.13 ± 0.65 1.67 ± 0.50 < 0.01
Periodontal SUV 1.83 ± 0.46 1.88 ± 0.45 0.39
  1. *Wilcoxon’s signed-rank test
  2. Abbreviations: MTX methotrexate, PSL prednisolone, ACPA anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, RF rheumatoid factor, MMP-3 matrix metalloproteinase 3, DAS Disease Activity Score